Quality of Life During Oral Peanut Immunotherapy in the OPIA Trial
Clinical & Experimental Allergy · 20.11.2026
DOI: 10.1111/cea.70476 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Experimental Allergy, online erschienen am 20.11.2026. Verfasst von Alice L. Flanagan und 4 weiteren Autor:innen. Die Arbeit nennt 50 Literaturangaben. Gefördert von: DBV Technologies, National Health and Medical Research Council.
Abstract (Originalsprache)
Background
Health‐related quality of life (HRQoL) findings have varied between peanut oral immunotherapy (OIT) trials. The objective of this study was to compare changes in the HRQoL between the OIT and standard (control) treatment groups during the OPIA peanut OIT double‐blind randomised controlled trial and at long‐term follow‐up.
Methods
OPIA was a single‐centre, 3‐arm, double‐blind placebo‐controlled trial of peanut OIT in children aged 10–16 years. Standardised questionnaires (FAQLQ, FAIM, FAQLQ‐Parent Burden, PSS) and bespoke surveys were administered at 0, 6, 12 and 13.5 months, with 3‐year follow‐up. Changes in scores at different time points were analysed descriptively and using 2‐tailed T tests. A GEE model investigated the interaction between change in HRQoL score, treatment (OIT vs. standard care) and time. 3 year follow‐up surveys were analysed using descriptive statistics and qualitative analysis.
Results
Sixty‐five subjects were randomised and 61 participants completed the study. There was no evidence of difference in HRQoL score changes between the OIT and standard treatment groups from baseline to 12 months or 13.5 months. Furthermore, achieving OPIA's primary efficacy endpoint (tolerance of ≥ 1000 mg of peanut protein (cumulative dose 1449 mg) at month 13.5 double blind placebo‐controlled food challenge was not associated with a more favourable change in FAQLQ from baseline to end of study. Changes in global FAQLQ‐Parent proxy (FAQLQ‐PF) scores from baseline to 12 months were less favourable for carers of children who had experienced treatment‐related serious adverse events compared to those without such events (mean change 0.10 vs. −0.97, 0.0063).
Conclusions
OIT did not confer a HRQoL benefit over standard care in this cohort, based upon the tools used to assess HRQoL. Treatment‐related serious adverse effects negatively impacted FAQLQ‐Parent proxy scores.
Förderung
- DBV Technologies
- National Health and Medical Research Council
Zitieren
APA
Flanagan, A. L., Bosi, I. M. L., Barnes, E. H., Hsu, P., & Campbell, D. E. (2026). Quality of Life During Oral Peanut Immunotherapy in the OPIA Trial. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.70476
Vancouver
Flanagan AL, Bosi IML, Barnes EH, Hsu P, Campbell DE. Quality of Life During Oral Peanut Immunotherapy in the OPIA Trial. Clinical & Experimental Allergy. 2026. doi:10.1111/cea.70476
BibTeX
@article{Flanagan2026,
author = {Flanagan, Alice L. and Bosi, Isabelle M. L. and Barnes, Elizabeth H. and Hsu, Peter and Campbell, Dianne E.},
title = {Quality of Life During Oral Peanut Immunotherapy in the OPIA Trial},
journal = {Clinical & Experimental Allergy},
year = {2026},
doi = {10.1111/cea.70476}
}
EUVIMED